Article
Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia.
HLA - 1 Jul 2022
Bendjelloul Mehdi, Usureau Cédric, Etancelin Pascaline, Saidak Zuzana, Lebon Delphine, Garçon Loïc, Marolleau Jean-Pierre, Desoutter Judith, Guillaume Nicolas
Abstract excerpt
After allogeneic hematopoietic stem-cell transplantation (alloHSCT), the chimerism assay is used to monitor cell engraftment and quantify the respective proportions of donor/recipient cells in blood or bone-marrow samples. Here, we aimed to better assess the utility of determining CD3+ cell chimerism within the first 6 months post alloHSCT. One hundred and thirty five patients diagnosed with acute myeloid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
